Angiocentric gliomas are pediatric low-grade gliomas (PLGGs) without known recurrent genetic drivers. We performed genomic analysis of new and published data from 249 PLGGs, including 19 angiocentric gliomas. We identified MYB-QKI fusions as a specific and single candidate driver event in angiocentric gliomas. In vitro and in vivo functional studies show that MYB-QKI rearrangements promote tumorigenesis through three mechanisms: MYB activation by truncation, enhancer translocation driving aberrant MYB-QKI expression and hemizygous loss of the tumor suppressor QKI. To our knowledge, this represents the first example of a single driver rearrangement simultaneously transforming cells via three genetic and epigenetic mechanisms in a tumor.
PLGGs encompass a heterogeneous group of World Health Organization (WHO) grade I and II tumors that collectively represent the most common pediatric brain tumor. PLGGs undergo frequent alterations in the mitogen-activated protein kinase (MAPK) pathway and in MYB family genes 1, 2 , including MYBL1 and MYB. Alterations in MYB are heterogeneous; several fusion partners have been reported as rare events in PLGGs 2 . The frequency of specific alterations and associations with histological subtypes are unknown.
Angiocentric gliomas arise in the cerebral cortex and share histological features with astrocytomas and ependymomas 3, 4 . We previously identified one angiocentric glioma with deletion of the 3′ region of MYB 1 , and one other angiocentric glioma has been reported to harbor a MYB-QKI rearrangement 2 . However, the nature and incidence of MYB alterations in angiocentric glioma has not been determined. Furthermore, the oncogenicity of MYB family transcription factors in the central nervous system and the mechanisms by which they contribute to gliomagenesis are yet to be defined.
To address these questions, we performed a combined analysis of newly generated and published PLGG genomic data sets 1, 2, 5 . We found MYB-QKI rearrangement to be the most common event involving a MYB family member and that this rearrangement was specific to angiocentric gliomas. We also found that this rearrangement contributes to oncogenicity through three mechanisms: generation of oncogenic MYB-QKI fusion protein, enhancer translocation that establishes an autoregulatory feedback loop selectively driving MYB-QKI expression and partial loss of expression of QKI, a tumorsuppressor gene.
RESULTS

Angiocentric gliomas exhibit recurrent MYB-QKI rearrangements
Previously published genomic analyses of PLGGs did not individually contain sufficient numbers of rare histological subtypes to achieve statistical power to detect recurrent aberrations. To address this, we performed a combined genomic analysis of whole-genome sequencing and/or RNA sequencing (RNA-seq) data from 172 PLGGs spanning ten histological subtypes (Supplementary Table 1 ), including 145 published samples 2, 5 and 27 rare PLGGs that were new to this study. We performed analyses of significantly recurrent somatic genetic events across all samples with whole-genome sequencing or RNAseq data ( Supplementary Fig. 1, Supplementary Tables 2 and 3 , and Supplementary Note). We observed recurrent somatic alterations in 154 tumors (90%), including all 140 tumors subjected to whole-genome MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism 2 7 4 VOLUME 48 | NUMBER 3 | MARCH 2016 Nature GeNetics A r t i c l e s sequencing. Rearrangements or structural alterations were observed in 129 tumors (83%; Fig. 1a and Supplementary Table 1) .
Rearrangements involving MYB family members (MYB and MYBL1) were the second most recurrent alteration, affecting 16 tumors (10%), predominantly diffuse astrocytomas and angiocentric gliomas ( Fig. 1a and Supplementary Fig. 1 ). Six of the seven angiocentric gliomas, including all tumors subjected to central pathology review, exhibited intrachromosomal deletions resulting in MYB-QKI rearrangements. The other angiocentric glioma, which was not centrally reviewed, contained a MYB-ESR1 rearrangement.
Although MYB rearrangements have been described in PLGGs 1,2 , we were struck by two new findings: QKI was the most frequent fusion partner, and MYB-QKI fusions were nearly universal in angiocentric glioma. For validation, we studied 12 additional angiocentric gliomas with only formalin-fixed, paraffin-embedded tissue available using targeted assays. Nine angiocentric gliomas were analyzed by FISH to detect MYB rearrangement or deletion (Fig. 1b) , and three angiocentric gliomas were analyzed by whole-exome sequencing and/or array comparative genomic hybridization (array CGH) ( Supplementary  Fig. 2 ). All 12 harbored MYB aberrations.
In total, all 19 angiocentric gliomas profiled by whole-genome sequencing, RNA-seq, whole-exome sequencing, FISH or array CGH displayed MYB alterations, and, in six of the seven cases in which the fusion partner of MYB could be detected, MYB was fused to QKI. In tumors confirmed to harbor MYB-QKI rearrangement, the genetic event appeared to be present in the majority of cells, although evidence of heterogeneity (aberration in ~50% of tumor cells) was observed with FISH analysis in two of five tumors with sufficient numbers of cells for quantitative scoring.
MYB-QKI rearrangements appeared to be specific to angiocentric glioma. None of the 147 non-angiocentric gliomas profiled with whole-genome sequencing or RNA-seq exhibited MYB-QKI fusions (P < 0.0001; Fig. 1c) . We also evaluated MYB alterations in an additional 65 PLGGs from two separate cohorts: ten non-angiocentric gliomas analyzed by FISH and 55 non-angiocentric gliomas evaluated by whole-exome sequencing and/or array CGH. Only one of these tumors exhibited alterations in MYB (as compared to 19/19 angiocentric gliomas; P < 0.0001) ( Supplementary Fig. 2 and Supplementary  Table 1 ). This tumor was designated not otherwise specified upon research review but had been diagnosed as angiocentric glioma at the referring institution. Five tumors evaluated by whole-exome sequencing or array CGH exhibited alterations of MYBL1; these tumors were all diffuse astrocytomas. The FISH assays, array CGH and wholeexome sequencing, although able to detect MYB alterations, were unable to characterize the fusion partners of MYB.
All MYB-QKI rearrangements had breakpoints within intron 4 of QKI, whereas the MYB breakpoint varied in its position from intron 9 to intron 15; all the rearrangements were predicted to result in the expression of an in-frame fusion protein, MYB-QKI (Fig. 1d) . We identified fusion mRNA transcripts by RNA-seq (Fig. 1d) and observed copy number breakpoints in these genes in whole-genome sequencing data (Fig. 1e) .
In the cohort analyzed by whole-genome sequencing and/or RNAseq, we also observed rearrangements involving QKI but not MYB in three supratentorial pilocytic astrocytomas and rearrangements involving MYB or MYBL1 but not QKI in nine tumors, seven of which were diffuse astrocytomas. Across the entire cohort of 172 tumors profiled with whole-genome sequencing and/or RNA-seq, 10% of tumors harbored alterations of either MYB family members or QKI.
MYB and QKI in brain development and cancer MYB proteins are transcription factors characterized by highly conserved DNA-binding motifs. First identified as v-Myb 6-8 , the cellular proto-oncoprotein counterpart c-MYB comprises an N terminus Figure 1 Recurrent rearrangement involving MYB and QKI in angiocentric gliomas. (a) Driver alterations were identified in 154 of 172 PLGGs profiled with whole-genome sequencing and/or RNA-seq (analysis includes both published 2, 5 sequences and tumors unique to this report). Histological subtypes included pilocytic astrocytoma (PA), pilomyxoid astrocytoma (PMA), angiocentric glioma (AG), oligodendroglioma (OD), diffuse astrocytoma (DA), dysembryoplastic neuroepithelial tumor (DNT), ganglioglioma (GG), pleomorphic xanthoastrocytoma (PXA) and PLGG not otherwise specified (NOS). Tumors for which histology is unavailable are designated NA. The dashed box highlights angiocentric gliomas.(b) FISH analysis using probes flanking MYB identifies three patterns in PLGG: MYB disomy, MYB rearrangement, or 3′ MYB deletion. Scale bars, 5 µm. (c) Frequency of MYB alterations and MYB-QKI rearrangements in diffuse astrocytoma and angiocentric glioma. The P value represents enrichment of MYB-QKI rearrangements in angiocentric glioma. MYB-QKI alterations were identified by whole-genome sequencing alone (n = 1), whole-genome sequencing and RNA-seq (n = 2), or RNA-seq alone (n = 3). (d) Breakpoints observed in MYB and QKI in angiocentric gliomas. Sequence across the breakpoints, as determined by RNA-seq, is shown for each rearrangement. (e) Copy number profiles from whole-genome sequencing data for MYB and QKI in three angiocentric gliomas. Arrows highlight breakpoints in MYB and QKI. npg A r t i c l e s that contains helix-turn-helix (HTH) DNA-binding motifs followed by a transcriptional activation domain and a C-terminal negative regulatory domain 9 . Full-length MYB is non-transforming or only weakly transforming in vitro 10 , but MYB proteins with a truncated C terminus are oncogenic [10] [11] [12] [13] . MYB-QKI breakpoints mapping between introns 9 and 15 of MYB are predicted to result in C-terminal truncation of the MYB protein.
MYB is not expressed in the postnatal brain cortex, where angiocentric gliomas occur. We examined RNA-seq data for normal tissues 14 and found that MYB expression was negligible in human brain cortex and substantially lower than MYB expression in colon, breast, blood, esophagus or skin (Fig. 2a) . Likewise, immunohistochemistry of adult human frontal cortex and white matter was negative for MYB (Fig. 2b,c) ; however, we detected high MYB expression in human fetal neural progenitor cells generated from the ganglionic eminence at 22 weeks of gestation (Fig. 2d,e) .
In mice, MYB was expressed in embryonic day (E) 14.5 neural progenitor cells of the ganglionic eminence subventricular region ( Fig. 2f-i) . In adult mice, we detected expression of MYB in the ependyma/ subventricular zone (Fig. 2j,k) , consistent with previous reports of MYB expression in mouse progenitor cells but not in cortical brain 15 .
QKI encodes the STAR (signal transduction and activation of RNA) RNA-binding protein Quaking, which has an essential role in oligodendroglial differentiation 16 and is widely expressed in the nervous system. Deletions of QKI have been suggested to be oncogenic in a number of human cancers, including glioblastoma 17 , prostate cancer 18 and gastric cancer 19 . In copy number analyses of 10,570 cancers from The Cancer Genome Atlas (TCGA) 20 , QKI was one of two genes in a deletion peak in adult glioblastoma (Fig. 2l) , renal clear cell carcinoma and cervical squamous cell carcinoma. It was also in larger peak regions of significant deletion in low-grade glioma and bladder and adrenocortical carcinomas. Focal QKI deletions were observed in over 10% of glioblastomas.
The MYB-QKI fusion protein is expected to retain the MYB Nterminal HTH DNA-binding motifs fused to the QKI C terminus (Fig. 2m) . The QKI N-terminal KH RNA-binding motif is lost, while C-terminal alternative splice sites are preserved. The MYB-QKI5 splice variant retains a nuclear localization sequence (NLS), which is not present in the MYB-QKI6 splice variant 21 . Fusions that contain only exons 1-9 of MYB also lose the MYB negative regulatory domain (designated as the short variant).
The findings that both MYB and QKI are disrupted suggest that MYB-QKI rearrangements may be oncogenic through the additive effects of alterations in both human MYB and QKI. The lack of expression of MYB in normal postnatal human cortical brain regions also suggests that rearrangement drives aberrant expression of the fusion allele. We therefore characterized mechanisms through which MYB-QKI rearrangements might contribute to aberrant MYB-QKI expression and evaluated the oncogenic potential of both genes.
MYB-QKI functions as a transcription factor
We performed genome-wide gene expression analyses of three independently generated pools of mouse neural stem cells (mNSCs) engineered to stably overexpress human MYB-QKI5, MYB-QKI6, truncated MYB encoded by exons 1-9 (MYBtr exons1-9 ) or enhanced GFP (eGFP). Relative to eGFP-expressing cells, those expressing MYB-QKI5 and MYB-QKI6 exhibited significantly different expression for 1,621 and 1,947 genes, respectively, with 1,029 genes overlapping (P < 0.0001; Supplementary Table 4) . Gene set enrichment analysis (GSEA) showed that expression of either MYBtr exons1-9 or the MYB-QKI isoforms was associated with enrichment of signatures of MYB pathway activation (P < 0.0001; Supplementary Table 5) . 
npg
A r t i c l e s
We defined a MYB-QKI gene expression signature comprising the 50 genes whose differential expression correlated most with the expression of the fusion protein (Fig. 3a) . These genes included Kit and Cdk6, previously reported to be associated with MYB activation 22 .
We performed chromatin immunoprecipitation with parallel sequencing (ChIP-seq) in mNSCs expressing MYB-QKI fusion protein, using one antibody that recognizes the N terminus of MYB and another antibody against acetylation of histone H3 at lysine 27 (H3K27ac), which defines the location of enhancer regions. We found that MYB-QKI5 bound 3,672 sites (P-value threshold = 1 × 10 −7 ) across the genome (92% of these sites contained a MYB binding motif) and H3K27ac was present at 9,122 sites, with an overlap of 1,907 sites (52% MYB binding sites, P < 0.0001) (Fig. 3b) . These findings are consistent with reports in T cell acute lymphoblastic leukemia (T-ALL), where MYB binding was highly correlated with H3K27ac-defined enhancers 23 . We also identified MYB-QKI binding to the endogenous Myb promoter (Supplementary Fig. 3a) .
MYB-QKI5 binding sites (P-value threshold = 1 × 10 −5 ) were located within 100 kb of 88% (22/25) of the upregulated genes in the MYB-QKI signature but only 40% (10/25) of the downregulated genes in the signature (P < 0.001; Fig. 3c) . Each of the MYB-QKI binding sites associated with an upregulated gene was associated with an H3K27ac-marked enhancer peak, whereas only 70% of the MYB-QKI binding sites at downregulated genes overlapped enhancers (P = 0.003).
The MYB-QKI fusion protein can activate transcription through binding of MYB consensus binding motifs. We generated a luciferase reporter construct using known MYB binding sites from the chicken mim-1 target promoter 8 and cotransfected this reporter construct together with construct encoding human MYBtr exons1-9 , MYB-QKI or full-length MYB into HEK293T cells. We observed a slight induction in mim-1 promoter activity with transfection to express full-length MYB as compared to the control vector. The greatest induction in mim-1 promoter activity was observed upon cotransfection of cells with the construct for MYBtr exons1-9 or MYB-QKI ( Fig. 3d and  Supplementary Fig. 3b) , with MYBtr exons1-9 resulting in the highest level of activity.
Angiocentric gliomas exhibited significantly higher expression of the MYB-QKI signature than normal pediatric brain (P = 0.001) and PLGGs without MYB-QKI alterations (P = 0.0011) (Fig. 3e) . PLGGs exhibited increased expression of genes associated with MYB pathway activation as compared to normal brain (P = 0.0003), but this increased expression was not specific to tumors with MYB-QKI rearrangement and was of lower magnitude than the difference observed for the MYB-QKI signature genes (Supplementary Fig. 3c ).
MYB-QKI rearrangements drive aberrant expression of truncated MYB
Angiocentric gliomas with MYB-QKI rearrangement exhibit significantly higher MYB expression than normal pediatric cortical brain (P = 0.0062) or PLGGs with BRAF or fibroblast growth factor receptor (FGFR) gene alterations (P = 0.03) (Fig. 4a and Supplementary Note) . The MYB transcript that is expressed in angiocentric gliomas is truncated and corresponds to the exons retained in the rearranged MYB-QKI allele. Three angiocentric gliomas harbored MYB-QKI rearrangement breakpoints between exons 9 and 10 of MYB. These tumors exhibited increased expression of MYB exons 1-9 relative to PLGGs that did not harbor MYB-QKI rearrangement (P < 0.05) but had minimal expression of the remaining MYB exons (Fig. 4b) . These data support selective, aberrant regulation of the expression of truncated MYB via MYB-QKI.
MYB-QKI rearrangement results in enhancer translocation
Aberrant oncogene expression can result from enhancer translocation 24 . In published H3K27ac enhancer profiles from normal human cortical brain samples 25 , the MYB locus is not associated with H3K27ac enhancer peaks, consistent with the finding that MYB is not expressed. In contrast, QKI, which is expressed, was associated with several H3K27ac peaks, including sequences at the 3′ end of QKI (Fig. 4c-e) . MYB-QKI rearrangement is predicted to bring these H3K27ac-associated enhancer elements from the 3′ end of QKI to within only 15 kb of the MYB promoter (Fig. 4e) .
Profiling of H3K27ac-associated enhancers for two human angiocentric gliomas expressing MYB-QKI confirmed the presence of active enhancer elements that are translocated proximally toward the MYB promoter ( Fig. 5a and Supplementary Fig. 4) . ChIP-seq analysis identified multiple H3K27ac peaks associated with the 3′ end of QKI, similar to the peaks observed in normal human brain and in a BRAF-duplicated supratentorial pilocytic astrocytoma. We also observed enhancers within 10 kb of the region 3′ to QKI and a larger cluster of super-enhancers 100-500 kb 3′ to QKI (Q3SE1 and Q3SE2). In angiocentric gliomas with MYB-QKI rearrangement, these enhancers are translocated proximally toward the MYB promoter (Fig. 5b) .
We observed an aberrant enhancer associated with the MYB promoter in MYB-QKI-defined angiocentric glioma (Fig. 5a) . Normal human cortical brain does not show evidence of MYBrelated enhancers, and, indeed, we did not observe the formation of H3K27ac enhancer peaks at MYB in the pilocytic astrocytoma (Supplementary Fig. 5 ). However, in both angiocentric gliomas, we observed a large H3K27ac peak associated with the MYB promoter (M5E1). RNA-seq showed expression of the first nine exons of MYB corresponding to those retained in the rearrangement, suggesting that the aberrant M5E1 enhancer is regulating expression of truncated MYB from the rearranged allele. The lack of expression of full-length MYB indicates that the aberrant enhancer does not regulate the expression of the remaining wild-type MYB allele.
We examined whether MYB-QKI fusion protein was able to functionally activate the MYB promoter by creating a luciferase reporter construct with the human MYB promoter upstream of the luciferase gene (MYB-luc). We observed significant induction of MYB promoter activity in human U87 glioma cells stably expressing MYB-QKI with the MYB-luc reporter as compared to U87 cells with the MYB-luc or promoterless control luciferase construct alone (Fig. 5c) . This suggests that MYB-QKI contributes to an autoregulatory feedback loop, possibly by binding to the MYB promoter. MYB-QKI activated the MYB promoter in two additional cellular contexts (HEK293T and NIH3T3 cells; Supplementary Fig. 6 ).
We predicted that enhancers in the 3′ UTR of QKI could aberrantly activate the MYB promoter when translocated, thereby further driving MYB-QKI expression. We cloned the proximal enhancer sequence from the QKI 3′ UTR (Q3E1) upstream of the human MYB promoter in the MYB-luc reporter construct. The baseline activity of the Q3E1-MYB-luc construct was higher than that of the MYB-luc construct in U87 cells (Fig. 5c) , with activation increased by approximately 1.5-fold, a level of activation shown to have biological relevance in other diseases 26 . Expression of MYB-QKI with the Q3E1-MYB-luc reporter led to even higher activity, again consistent with an npg autoregulatory feedback loop in the presence of the fusion protein (Fig. 5c) .
MYB-QKI fusion protein is oncogenic
Expression of truncated MYB has previously been reported to be oncogenic [10] [11] [12] . In mNSCs, overexpression of truncated MYB from exons 1-9 (short variant) increased the cell proliferation rate in comparison to eGFP control ( Fig. 6a and Supplementary Fig. 6b ), and in NIH3T3 cells overexpression of human MYBtr exons1-15 but not fulllength MYB induced tumor formation when cells were injected into mouse flanks ( Fig. 6b and Supplementary Fig. 6b ). Furthermore, mNSCs expressing human truncated MYB induced diffuse glioma formation by 100 d, on average, after intracranial injection in mice (Fig. 6e,f) . These tumors expressed OLIG2 and GFAP protein in a subset of tumor cells, a pattern similar to that observed in human diffuse gliomas (Supplementary Fig. 6c ).
To test whether MYB-QKI fusions are oncogenic, we stably expressed human MYB-QKI5 and MYB-QKI6 in mNSCs and NIH3T3 cells. In mNSCs, overexpression of either isoform led to a significantly increased proliferation rate as compared to expression of eGFP (P < 0.0001; Fig. 6c and Supplementary Fig. 6b) . Similarly, both isoforms induced anchorage-independent growth when overexpressed in NIH3T3 cells (Supplementary Fig. 7a) . In vivo, overexpression of both MYB-QKI5 and MYB-QKI6 in NIH3T3 cells but not of fulllength MYB led to tumor formation as flank xenografts (Fig. 6d) . Intracranial injections with mNSCs overexpressing MYB-QKI5 or MYB-QKI6 resulted in glioma formation and infiltrating tumor cells, with some evidence of enhanced growth around vessels and a clustered growth pattern, features similar to those of angiocentric glioma and distinct from the histology seen in models of adult glioblastoma (for example, EGFRvIII overexpression in Ink4a/Arf −/− mNSCs) 27 . However, these tumors differed from human angiocentric gliomas in that they had high-grade features with frequent mitoses and marked cytological atypia (Fig. 6e) . Immunohistochemical analysis showed diffuse GFAP expression and a subset of OLIG2-positive tumor cells, a pattern similar to that seen in human angiocentric gliomas (Supplementary Fig. 6c) .
In total, we established flank injections in 15 mice of NIH3T3 cells overexpressing either truncated MYB or MYB-QKI fusion protein (five vector controls) and intracranial injections in 29 mice of mNSCs expressing truncated MYB or MYB-QKI fusion protein (15 vector controls) (Supplementary Fig. 7b) . We observed flank tumors in all 15 mice injected with NIH3T3 cells overexpressing either truncated MYB or MYB-QKI and five intracranial tumors from mice injected with mNSCs expressing truncated MYB or MYB-QKI. We did not observe tumors formation from any cells expressing vector control. These data represent a significant enrichment of tumor formation in cells expressing truncated MYB or MYB-QKI fusion protein (P < 0.0001).
MYB-QKI rearrangement disrupts QKI, a tumor suppressor
We were interested in understanding how disruption of QKI might contribute to oncogenicity in tumors that harbor MYB-QKI rearrangement. Exon-specific RNA-seq analysis of angiocentric gliomas with MYB-QKI rearrangement (n = 4) showed reduced expression of QKI as compared to PLGGs that harbored BRAF alterations (n = 5) (Fig. 7a and Supplementary Note) . These data suggest that the MYB-QKI rearrangement might contribute to tumor formation through reduced expression of QKI, a tumor-suppressor gene.
Indeed, suppressing wild-type Qk using short hairpin RNAs (shRNAs) that targeted the first four exons of Qk led to increased proliferation of mNSCs, with the greatest increase observed in the context of preexisting human MYB-QKI expression. In mNSCs overexpressing human truncated MYB, MYB-QKI5 or MYB-QKI6, suppression of wild-type Qk was sufficient to increase proliferation within only 3 d of suppression (Fig. 7b and Supplementary Fig. 8a ). The greatest effect was observed in cells overexpressing MYB-QKI fusion protein, despite a similar or lower degree of suppression of Qk in these cells as compared to cells overexpressing eGFP or truncated MYB. We did not observe increased proliferation within 3 d of suppression in cells expressing eGFP, although we did observe a mild increase in proliferation on day 5 (Supplementary Fig. 8b ). These data suggest that MYB-QKI overexpression and QKI suppression exert cooperative functional effects.
Suppression of Qk by shRNA in mNSCs expressing MYB-QKI6 led to differential expression of 309 genes relative to cells instead expressing control shRNA to lacZ (q < 0.25; Supplementary Table 6 ). QKI has previously been reported to regulate the expression of microRNAs (miRNAs) 28, 29 , and we also observed upregulation of ten miRNAs with suppression of wild-type Qk, including miR-717 (Supplementary Table 7 ). Isoform 7 of mouse Qk is predicted to contain a miRNA regulatory element (MRE) for miR-717 (ref. 30) .
Angiocentric gliomas exhibit molecular effects consistent with QKI suppression. In mNSCs, we defined a signature consisting of the 50 genes whose expression was most correlated with Qk suppression (Supplementary Fig. 8c ). This signature was significantly enriched in angiocentric gliomas relative to normal human brain (P < 0.0001; Fig. 7c) .
Taken together, our data suggest three mechanisms through which MYB-QKI rearrangement contributes to oncogenicity (Fig. 8) . First, npg A r t i c l e s the alteration results in proximal translocation of H3K27ac-bound enhancers in the 3′ region of QKI to the MYB promoter, resulting in MYB promoter activation. Second, the MYB-QKI fusion protein that is expressed is oncogenic, functions as a transcription factor and exhibits the ability to bind to and activate the MYB promoter, resulting in an autoregulatory feedback loop. Third, hemizygous loss of QKI results in suppression of QKI, which functions as a tumor-suppressor gene. Thus, disruptions of both MYB and QKI appear to contribute to tumor formation in a cooperative manner.
DISCUSSION
We describe MYB-QKI as a new recurrent diagnostic fusion in angiocentric glioma. It also represents the first example, to our knowledge, of a single driver translocation of two genes resulting in the aberrant expression of an activated oncogenic fusion protein that then participates in an autoregulatory feedback loop, proximal translocation of enhancer elements regulating fusion gene expression and simultaneous functional loss of a tumor-suppressor gene. We found MYB-QKI rearrangement to be a defining event in angiocentric glioma. This has important implications for the treatment and diagnosis of this disease. The tight association of the translocation with this histology supports pathological classification of angiocentric glioma as a separate biological entity. We propose that the presence of this fusion should be considered diagnostic for angiocentric glioma. This could aid in distinguishing angiocentric gliomas from tumors with higher potential for recurrence or that require further treatment, such as IDH-mutant diffuse gliomas or ependymomas.
MYB-QKI expression was sufficient to reproducibly generate intracranial tumors. Angiocentric gliomas are WHO grade I tumors and exhibit a very low mitotic index. Successful models of low-grade pediatric or adult gliomas are rare across all histologies. The low penetrance for mNSCs (five tumors in 29 attempts) relative to highgrade glioma models (for example, overexpression of EGFRvIII in Ink4a/Arf −/− mNSCs) 27 suggests that genetic drivers of low-grade gliomas may be borderline sufficient for transformation.
Although the development of small molecule inhibitors to directly target MYB is likely to be challenging, MYB-QKI transcriptional targets such as KIT or CDK6 can be targeted. The association of MYB-QKI with H3K27ac-bound enhancer elements also raises the possibility of therapeutically inhibiting the effects of the fusion through indirect mechanisms, such as BET bromodomain 31, 32 or CDK7 (ref. 33) inhibition.
Adenoid cystic carcinomas harbor MYB-NFIB alterations [34] [35] [36] . Like MYB-QKI, MYB-NFIB fusion also results in high levels of MYB expression, although the mechanism underlying this expression pattern, the functional role of NFIB and the oncogenicity of MYB-NFIB remain undefined.
We observed an additive effect for Qk suppression and MYB-QKI overexpression, confirming QKI as a tumor suppressor and suggesting cooperation between its loss and expression of MYB-QKI. Recent studies indicate a diversity of roles for QKI in cancer, including the alteration of splicing events 37 and a role in epithelial-to-mesenchymal transition via regulation of circular RNAs 38 . QKI regulates the expression of genes implicated in cancer 39 and miRNA processing 30 . Further investigation is required to evaluate mechanisms of cooperativity between QKI suppression and MYB-QKI expression.
Angiocentric gliomas exhibit haploinsufficiency for QKI, whereas glioblastomas demonstrate biallelic loss of this gene. One explanation for the haploinsufficiency in angiocentric gliomas may be that complete loss of QKI exerts negative selection in the developing brain. This hypothesis is supported by the essential role of QKI in oligodendrocytic differentiation. Haploinsufficiency may also account for the lower-grade nature of angiocentric gliomas as compared to glioblastomas.
Pediatric tumors are characterized by simple genomes with single driver alterations 40, 41 . Our findings that one rearrangement contributes to oncogenicity through multiple mechanisms may be applicable to a large number of pediatric tumors.
URLs. SAMtools, http://www.samtools.sourceforge.net/; Picard, http://broadinstitute.github.io/picard/; bamliquidator, https://github. com/BradnerLab/pipeline/wiki/bamliquidator.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Microarray data have been accessioned with the Gene Expression Omnibus (GEO) under series GSE75796. The sequence reported in this paper (whole-exome sequencing, wholegenome sequencing, RNA-seq and ChIP-seq) has been deposited in the database of Genotypes and Phenotypes (dbGaP) under study accession phs001054.v1.p1. and the MluI site was further used to clone candidate enhancer regions upstream of the MYB promoter. The human QKI 3′ UTR enhancer sequences (hg18, chr. 6: 163,920,360-163,920,809 and chr. 6: 163,921,548-163,921,972) were synthesized by Invitrogen and cloned into the reporter constructs as described above. LightSwitch Random Promoter Control 1 (Active Motif) containing a 1-kb non-conserved, non-genic and non-repetitive fragment from the human genome cloned upstream of the RenSP luciferase reporter gene was used as a negative control. A reporter vector with a housekeeping gene promoter, LightSwitch ACTB Promoter Control, was used as a positive control for all assays. The luciferase reporter constructs containing the MYB promoter alone or together with enhancers were transfected into the U87 glioma line (or a U87 line stably expressing MYB-QKI) using Lipofectamine 3000 (n = 5) or cotransfected with MYB-QKI or vector control into HEK293T cells via Lipofectamine 2000 (Invitrogen) or into NIH3T3 lines stably expressing MYB-QKI using PolyFect (Qiagen). Luciferase activity was quantified 24 h after transfection using LightSwitch Luciferase Assay Reagent (Active Motif) according to the manufacturer's protocol.
mim-1 reporter construct generation and MYB transactivation assays.
Luciferase reporter constructs containing a consensus DNA-binding sequence for c-MYB were generated. The reporter construct was designed using the core MYB recognition element (MRE) consensus sequence PyAAC(G/T)G, which is present in the mim-1 gene promoter, a previously described MYB target 8 . Double-stranded oligonucleotides were generated by annealing primers mim-1 forward and mim-1 reverse (Supplementary Table 9 ). The annealed oligonucleotide was ligated into pGL4.10[luc2] vector (Promega) digested with XhoI and HindIII. The pRL Renilla luciferase reporter vector (Promega, E2261) served as an internal control in all assays. The mim-1 reporter construct and pRL Renilla vector (at a ratio of 30:1) were cotransfected into HEK293T cells along with indicated fusions or controls via Lipofectamine 2000. Luciferase activity was quantified 24 h after transfection using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol. a P-value threshold for enrichment of 1 × 10 −5 . Super-enhancer analysis was performed as previously described 67 .
In vivo experiments. Mouse flank tumor studies with NIH3T3 stable cell lines. NIH3T3 cell lines were injected subcutaneously into the flanks of NSG mice (five mice for each cell line). Mice were 6-10 weeks of age, with equal representation of male and female mice. Tumor growth was measured biweekly. Ellipsoid tumor volume was calculated using the formula volume = 1/2(length × width 2 ).
For intracranial mouse injections, neurospheres were dissociated and resuspended at 100,000 viable cells/µl. One microliter was injected into the right striatum of immunocompromised ICR-SCID mice. Mice were monitored and euthanized at the onset of neurological symptoms. Brains were subjected to routine histological analysis. Tumors were scored as present on the basis of identification of atypical cells by a neuropathologist. Four-to six-week-old male IcrTac:ICRPrkdc-Scid mice from Taconic were used. A total of 44 mice were used.
Mouse injections were not randomized nor were experimenters blinded to mouse identity. Sample size was not predetermined. Qualitative assessment of tumorigenicity was the primary outcome measured. Neuropathologists were blinded to group allocation.
Statistical analysis.
For statistical analysis (unless otherwise described), P values were calculated using Fisher's exact tests, t tests or Pearson's tests as appropriate. ANOVA with correction was used for comparison of multiple groups. Log-rank (Mantel-Cox) survival analysis was performed for mouse studies, and Kaplan-Meier curves were generated. The error bars shown depict s.e.m.
